Literature DB >> 17563209

The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans.

Eric D Collins1, Suzanne K Vosberg, Amie S Ward, Margaret Haney, Richard W Foltin.   

Abstract

This study examined the acute effects of pretreatment with high-dose memantine, an N-methyl-D-aspartate antagonist, on the effects of cocaine in humans. Six African American men completed this laboratory study, in which, following pretreatment with memantine (0 or 60 mg), they had 5 opportunities to smoke cocaine base (0, 12, 25, or 50 mg) or receive an alternative reinforcer ($5.00 merchandise voucher). Cocaine alone produced the well-documented dose-dependent increases in cardiovascular activity and ratings of positive mood. Maximal systolic blood pressure was elevated during memantine pretreatment days. Peak ratings of "I feel stimulated" and "I feel anxious" were also higher with memantine pretreatment. However, memantine pretreatment did not alter the choice to self-administer cocaine. These data suggest that memantine pretreatment may not be helpful in the treatment of cocaine dependence. (c) 2007 APA, all rights reserved

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563209     DOI: 10.1037/1064-1297.15.3.228

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  15 in total

1.  A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.

Authors:  Adam Bisaga; Efrat Aharonovich; Wendy Y Cheng; Frances R Levin; John J Mariani; Wilfrid N Raby; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

2.  Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism.

Authors:  S Jamadar; E E DeVito; R E Jiantonio; S A Meda; M C Stevens; M N Potenza; J H Krystal; G D Pearlson
Journal:  Psychopharmacology (Berl)       Date:  2012-02-04       Impact factor: 4.530

3.  A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.

Authors:  Adam Bisaga; Maria A Sullivan; Wendy Y Cheng; Kenneth M Carpenter; John J Mariani; Frances R Levin; Wilfrid N Raby; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2011-06-28       Impact factor: 4.492

Review 4.  Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.

Authors:  Frank N Perkins; Kevin B Freeman
Journal:  Pharmacol Biochem Behav       Date:  2017-06-27       Impact factor: 3.533

Review 5.  Cocaine choice procedures in animals, humans, and treatment-seekers: Can we bridge the divide?

Authors:  Scott J Moeller; William W Stoops
Journal:  Pharmacol Biochem Behav       Date:  2015-09-30       Impact factor: 3.533

Review 6.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 7.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

Review 8.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Relationship between intranasal cocaine self-administration and subject-rated effects: predictors of cocaine taking on progressive-ratio schedules.

Authors:  Justin C Strickland; Joshua A Lile; Craig R Rush; William W Stoops
Journal:  Hum Psychopharmacol       Date:  2014-05-19       Impact factor: 1.672

Review 10.  Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.

Authors:  Stuart J Thomas; George T Grossberg
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.